RTTNews BiotechDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:37:42·⟳ 抓取 21:00:14 +22m32s·⚡ 决策 09-14 21:08:11 +7m57s·43.0 天前
Organon 的 MIUDELLA 六年有效期 sNDA 获 FDA 受理审评，PDUFA 决议在 2027 年二季度
这是“受理审评(sNDA accepted for review)”而非获批，属于药物监管路径中低信息量的程序性步骤；真正催化（PDUFA 决议）在约 2027 年二季度，产品本身 2026 年底才商业化，短期无业绩增量。对 Organon 这种数十亿美元营收体量的公司，单凭受理新闻缺乏短线正期望与明确触发窗口。
📄 原文RTTNews Biotech↗ 原文
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Organon & Co.（OGN.US）
sNDA 获受理是低预期差的程序性里程碑（非获批），PDUFA 决议在约 2027Q2、产品 2026 年底才上市，短期无收入或指引增量；对 Organon 体量边际弹性小、且盘前已快速扩散，缺乏可交易短线 edge，等待 PDUFA/上市放量等实质节点。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FDA 受理 MIUDELLA 有效期从 3 年延至 6 年的 sNDA 方向正面，但仅是受理、非批准，决议远在 2027Q2，且产品尚未上市、短期无收入贡献；对 Organon 不构成有 edge 的短线交易，回避。
消息传播链
- 盘前 07:36 ET TheFly 即报道 Organon 宣布 FDA 受理 Sebela 的 MIUDELLA sNDA，是当前可见最早转述，说明消息在盘前已快速进入财经终端。
- RTTNews 08:37 ET 发稿并被 Nasdaq 等转载，明确 PDUFA 在 2027Q2、产品 2026 年底上市，属低增量程序性消息。
- Organon 6 月 22 日已公告完成 MIUDELLA 独家许可，本次受理的产品/权益背景并非新信息，削弱边际惊喜。
关键理由
- 事件性质为“受理”而非“批准”，主要消除的是申报能否立上的程序性不确定，预期差和股价弹性都很小。
- 真正催化（PDUFA）在约 2027Q2、MIUDELLA 2026 年底才上市，当前时间窗内无可兑现的收入或指引上修。
主要风险
- 若市场将受理误读为接近获批而短线高开，盘前情绪可能透支、随后回落（见光死/买预期风险）。
- 最终可能拿到完整决议(CRL)或附加 REMS/标签限制；六年有效期能否落地仍未知。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-09-14 · 影响 weakens
正文明确仅 accepted for review（非 approved），PDUFA 在 2027Q2，产品 2026 年底才上市——做多的近期业绩与时间窗依据不足，弱化 LONG 逻辑。
检索:MIUDELLA sNDA accepted vs approved; near-term revenue / launch timing / materiality to Organon 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例/经验不支持把受理当成可交易利好，最终选择 AVOID，等待 2027Q2 PDUFA 或商业化放量这类实质节点。
方向:无高相似同市场对齐先例；但生物医药监管阶段经验一致表明“sNDA 受理(accepted for review)”是程序性步骤，不等于获批，价格反应通常弱于 PDUFA 批准本身。
涨幅量级:缺乏干净、锚定受理时点的对齐先例，无法可靠校准涨幅，故不用任何先例设定 tp/sl；在缺少量级依据时不做。
形态:程序性监管里程碑（受理/立卷）较常见的模式是消息当日小幅波动、缺乏持续性，真正行情集中在 PDUFA 决议或 AdCom；不足以支撑追高。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 24 ms
{"result": "search_processed_events:agent query=`organon miudella snda fda accepted six years | organon ogn copper iud miudella duration extension pdufa | sebela miudella organon license`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常 - fetch_decision_experience 成功 stock_tools HTTP · 12 ms
{ - web_search 成功 doubao_search · 2,594 ms
豆包搜索结果（原始查询:Organon MIUDELLA sNDA FDA accepted six years press release September 2026；API SearchType:web）
原文全文
展开原文 · 9,434 字
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
By
RTTNews Staff Writer
✉
Published:
9/14/2026 8:37 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Organon (
OGN
) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MIUDELLA, a hormone-free copper intrauterine device (IUD), seeking to extend its approved duration of use from three to six years.
The FDA's Prescription Drug User Fee Act (PDUFA) action is expected in the second quarter of 2027.
MIUDELLA is currently approved in the U.S. for prevention of pregnancy in females of reproductive potential for up to three years and is anticipated to become commercially available in late 2026.
The product was investigated in three U.S. clinical trials involving 1,904 women aged 17 to 45 years.
In the Phase 3 efficacy cohort of women aged 17 to 35 years, MIUDELLA demonstrated a first-year Pearl Index of 0.94 and a cumulative three-year Pearl Index of 1.05, corresponding to approximately 99% contraceptive effectiveness.
MIUDELLA Clinical Profile
The pivotal Phase 3 study was a prospective, multicenter, single-arm, open-label trial conducted across 42 U.S. centers. The primary endpoint evaluated contraceptive efficacy through three years using the Pearl Index.
The overall placement success rate was approximately 99%.
The most common adverse reactions reported in clinical trials included heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage and dyspareunia.
Discontinuation due to bleeding or pain adverse events declined from 8.5% in the first year to 3.2% by year three, while expulsion rates declined from 1.9% in year one to 0.9% in year three.
Organon-Sebela Agreement
Organon completed an agreement in June 2026 to exclusively license global rights to MIUDELLA from Sebela Women's Health.
If approved for six years of use, the expanded duration could broaden MIUDELLA's contraceptive positioning and provide women with a longer-term, hormone-free option.
MIUDELLA is currently subject to a Risk Evaluation and Mitigation Strategy (REMS), requiring healthcare providers to complete certification and training on proper insertion before using the device.
Near-term Catalyst
The key upcoming catalyst for Organon is the FDA's regulatory decision on the MIUDELLA sNDA, with PDUFA action expected in Q2 2027.
FDA approval
of the six-year indication would extend the duration of use for the hormone-free IUD and potentially strengthen Organon's women's
health
portfolio as MIUDELLA enters the U.S. commercial market.
OGN has traded between $5.69 and $13.78 over the past year. The stock closed Friday's trading (September 11, 2026) at $13.64, up 0.07%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
By
RTTNews Staff Writer
✉
Published:
9/14/2026 8:37 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Organon (
OGN
) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MIUDELLA, a hormone-free copper intrauterine device (IUD), seeking to extend its approved duration of use from three to six years.
The FDA's Prescription Drug User Fee Act (PDUFA) action is expected in the second quarter of 2027.
MIUDELLA is currently approved in the U.S. for prevention of pregnancy in females of reproductive potential for up to three years and is anticipated to become commercially available in late 2026.
The product was investigated in three U.S. clinical trials involving 1,904 women aged 17 to 45 years.
In the Phase 3 efficacy cohort of women aged 17 to 35 years, MIUDELLA demonstrated a first-year Pearl Index of 0.94 and a cumulative three-year Pearl Index of 1.05, corresponding to approximately 99% contraceptive effectiveness.
MIUDELLA Clinical Profile
The pivotal Phase 3 study was a prospective, multicenter, single-arm, open-label trial conducted across 42 U.S. centers. The primary endpoint evaluated contraceptive efficacy through three years using the Pearl Index.
The overall placement success rate was approximately 99%.
The most common adverse reactions reported in clinical trials included heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage and dyspareunia.
Discontinuation due to bleeding or pain adverse events declined from 8.5% in the first year to 3.2% by year three, while expulsion rates declined from 1.9% in year one to 0.9% in year three.
Organon-Sebela Agreement
Organon completed an agreement in June 2026 to exclusively license global rights to MIUDELLA from Sebela Women's Health.
If approved for six years of use, the expanded duration could broaden MIUDELLA's contraceptive positioning and provide women with a longer-term, hormone-free option.
MIUDELLA is currently subject to a Risk Evaluation and Mitigation Strategy (REMS), requiring healthcare providers to complete certification and training on proper insertion before using the device.
Near-term Catalyst
The key upcoming catalyst for Organon is the FDA's regulatory decision on the MIUDELLA sNDA, with PDUFA action expected in Q2 2027.
FDA approval
of the six-year indication would extend the duration of use for the hormone-free IUD and potentially strengthen Organon's women's
health
portfolio as MIUDELLA enters the U.S. commercial market.
OGN has traded between $5.69 and $13.78 over the past year. The stock closed Friday's trading (September 11, 2026) at $13.64, up 0.07%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。